Brief: Pulmatrix Announces FDA Acceptance Of Ind Application For Pur3100 To Treat Acute Migraine
19/09/2023 14:10
Sept 19 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR
PUR3100 TO TREAT ACUTE MIGRAINE
* PULMATRIX INC - RECEIVED A STUDY MAY PROCEED LETTER FOR A
PHASE
2 STUDY TO EVALUATE PUR3100
Source text for Eikon: ID:nPn8cYkNKa
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM